Difamilast
Small moleculeexperimental
Clinical trial activity
16 trials · 3 clinical orgs · 0 marketing orgs
Phase 1
2
Phase 2
14
Phase 3
10
Phase 4
0
Earliest trial started Aug 1, 2012 (NCT01702181)
Timeline
Indications
Studied for
Mechanism of action
- Phosphodiesterase 4AINHIBITOR
PDE4A inhibitor
- Phosphodiesterase 4INHIBITOR
Phosphodiesterase 4 inhibitor
Selectivity for PDE4B
Chemistry & pharmacology
Loading structure…
SMILES
CCOc1ccccc1C(=O)NCc1coc(-c2ccc(OC(F)F)c(OC(C)C)c2)n1- Mol. weight
- 446.45 g/mol
- Lipinski Ro5
- 1 violation(s)
- Rule of 3
- No
- Chirality
- Achiral Molecule
- Inorganic
- No
- Polymer
- No
Oral
No
Parenteral
No
Topical
No
Sources
- ChEMBLCHEMBL3989968 ↗
Also known as
- mm36
- mm36
- opa-15406
- opa-15406
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT07173478 | Phase 3 | Oct 31, 2025 | Otsuka |
| NCT07184645 | Phase 3 | Sep 30, 2025 | Otsuka |
| NCT05667623 | Phase 3 | Jan 30, 2023 | Otsuka |
| NCT05650320 | Phase 3 | Dec 30, 2022 | Otsuka |
| NCT05608343 | Phase 3 | Oct 1, 2022 | Acrotech Biopharma LLC |
| NCT05571943 | Phase 3 | Sep 15, 2022 | Acrotech Biopharma LLC |
| NCT05372653 | Phase 3 | May 23, 2022 | Otsuka |
| NCT03961529 | Phase 3 | May 14, 2019 | Otsuka |
| NCT03911401 | Phase 3 | May 7, 2019 | Otsuka |
| NCT03908970 | Phase 3 | Mar 25, 2019 | Otsuka |
| NCT03018691 | Phase 2 | Jan 1, 2017 | Otsuka |
| NCT02945657 | Phase 2 | Oct 1, 2016 | Medimetriks |
| NCT02914548 | Phase 2 | Sep 1, 2016 | Otsuka |
| NCT02334787 | Phase 1 | Jan 1, 2015 | Otsuka |
| NCT02068352 | Phase 2 | Jun 1, 2014 | Otsuka |
| NCT01702181 | Phase 1 | Aug 1, 2012 | Otsuka |
Showing 16 of 16 trials
Page 1 / 1
Organizations
Research & Development (3)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Otsuka | For profit | 13 | 13 | 3 | 2012 |
| Acrotech Biopharma LLC | For profit | 2 | 2 | 1 | 2022 |
| Medimetriks | For profit | 1 | 1 | 1 | 2016 |
3 organizations
Page 1 / 1